Author Login

Correspondence to Author: Nioola Cotagno, Emaw Conakta Manno, Andeerea Finccy, Stefania Bernardi, Luna Colagrossi, Leonrda Gentile,Cristen Russo, Caroleo Federio Perno, Paolo Rossa, Catrina Canrini, Paola Palima. 

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Abstract:

Remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies were among the several treatment medications used to treat a patient with activated PI3K-kinase delta syndrome (APDS) and a persistent, asymptomatic SARS-CoV-2 infection. Seven days after the delivery of the monoclonal antibody and 105 days after the first positive swab, we saw the virus’s elimination. All analyzed samples had wild type SARSCoV-2 viral results at genotyping. This instance demonstrates the good tolerability and effectiveness of monoclonal antibodies in lowering viral shedding in chronic illnesses that are resistant to other therapies.

Keywords: SARS-CoV-2, COVID19, IEI, activated PI3K delta syndrome (APDS), monoclonal antibody, remdesivir, long-lasting infection, APDS.

Citation:

Dr.Nioola Cotagno, Successful Treatment With Monoclonal Antibodies In One Apds Patient With Prolonged Sars-Cov-2 Infection Not Responsive To Previous Lines Of Treatment. Journal of Antibodies 2025.